Oncolytics Biotech Inc.
ONC.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -49.43% | 15.97% | 8.88% | -97.31% | 5.44% |
| Total Depreciation and Amortization | -12.34% | -5.17% | -25.88% | -27.23% | 0.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,630.76% | 550.99% | 233.66% | 126.82% | 143.81% |
| Change in Net Operating Assets | -40.62% | -199.36% | -2,328.98% | -161.14% | 15.49% |
| Cash from Operations | -36.31% | 20.65% | 18.27% | -24.52% | 21.20% |
| Capital Expenditure | 78.30% | -- | -- | -95.45% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 78.30% | -- | -- | -95.45% | -100.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -26.25% | -56.92% | 0.00% | 3.85% | 21.57% |
| Issuance of Common Stock | 1,444.60% | 191.43% | 273.16% | -- | -98.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 48.95% | -550.38% | -230.99% | -106.20% | 84.30% |
| Cash from Financing | 2,469.40% | 169.06% | 270.10% | 86.29% | -100.80% |
| Foreign Exchange rate Adjustments | 213.32% | -332.76% | -104.10% | 221.76% | -148.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 57.12% | 85.91% | 88.69% | 29.90% | -123.00% |